News Releases

IMPORTANT SAFETY INFORMATION ON BCR-ABL TYROSINE KINASE INHIBITORS [GLEEVEC® (IMATINIB MESYLATE), TASIGNA® (NILOTINIB), BOSULIFTM (BOSUTINIB), SPRYCEL® (DASATINIB), ICLUSIG® (PONATINIB HYDROCHLORIDE)] AND RISK OF HEPATITIS B REACTIVATION

Audience: Healthcare Professionals (medical oncologists, hematologists, gastroenterologists, oncology nurses, pharmacists) pharmacy associations, medical associations, chiefs of medicine in hospitals, hospital pharmacy chiefs) and patient groups.

 

04/05/16